(Q37990891)

26 August 2017

Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus (English)

1 reference

26 August 2017

0 references

0 references

Niren K Shah

1

1 reference

26 August 2017

Wasim E Deeb

series ordinal

2

1 reference

26 August 2017

Rushab Choksi

series ordinal

3

1 reference

26 August 2017

Benjamin J Epstein

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

32

1 reference

26 August 2017

1

1 reference

26 August 2017

80-94

1 reference

Global estimates of the prevalence of diabetes for 2010 and 2030

26 August 2017

1 reference

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

21 January 2018

1 reference

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress.

21 January 2018

1 reference

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.

21 January 2018

1 reference

21 January 2018

1 reference

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

21 January 2018

1 reference

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

Facilitative glucose transporters: regulatory mechanisms and dysregulation in diabetes

21 January 2018

1 reference

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

Active sugar transport in health and disease

21 January 2018

1 reference

Molecular biology of mammalian glucose transporters

21 January 2018

1 reference

The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function.

21 January 2018

1 reference

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

21 January 2018

1 reference

Surprising versatility of Na+-glucose cotransporters: SLC5.

21 January 2018

1 reference

Functional properties and genomics of glucose transporters

21 January 2018

1 reference

Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters

21 January 2018

1 reference

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

21 January 2018

1 reference

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

21 January 2018

1 reference

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

21 January 2018

1 reference

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

Sodium-glucose transporter-2 inhibition as an antidiabetic therapy

21 January 2018

1 reference

Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

Urinary tract infections in women with type 1 diabetes mellitus: survey of female participants in the epidemiology of diabetes interventions and complications study cohort.

21 January 2018

1 reference

The Sweet Pee model for Sglt2 mutation

21 January 2018

1 reference

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

21 January 2018

1 reference

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

21 January 2018

1 reference

The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats

21 January 2018

1 reference

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

Sulfonylurea induced beta-cell apoptosis in cultured human islets

21 January 2018

1 reference

Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose

21 January 2018

1 reference

Impact of family history of diabetes on the assessment of beta-cell function.

21 January 2018

1 reference

Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1010

1 reference

26 August 2017

1 reference